Page 87 - Demo
P. 87


                                    ANALESRANFwww.analesranf.com24. Wrobleski ST, Moslin R, Lin S, Zhang Y, SpergelS, Kempson J, et al. Highly SelectiveInhibition of Tyrosine Kinase 2 (TYK2) for theTreatment of Autoimmune Diseases:Discovery of the Allosteric Inhibitor BMS986165. J Med Chem. 2019 Oct 24; 62(20):8973-8995.doi:10.1021/acs.jmedchem.9b00444 25. Lesage A, Marceau F, Gibson C, Loenders B,Katzer W, Ambrosi HD, Saupe J, Faussner A,Pardali E, Knolle J. In vitro pharmacologicalprofile of PHA-022121, a small moleculebradykinin B2 receptor antagonist in clinicaldevelopment. Int Immunopharmacol. 2022Apr; 105: 108523.doi:10.1016/j.intimp.2022.108523 26. Jansen-van Vuuren RD, Jedlov%u010dnik L, Ko%u0161mrlj J,Massey TE, Derdau V. Deuterated Drugs andBiomarkers in the COVID-19 Pandemic. ACSOmega. 2022 Nov 13; 7(46): 41840-41858.doi:10.1021/acsomega.2c04160 27. Zesiewicz T, Heerinckx F, De Jager R, OmidvarO, Kilpatrick M, Shaw J, Shchepinov MS.Randomized, clinical trial of RT001: Earlysignals of efficacy in Friedreich%u2019s ataxia. MovDisord. 2018 Jul; 33(6): 1000-1005.doi:10.1002/mds.27353 28. Demidov VV. Site-specifically deuteratedessential lipids as new drugs againstneuronal, retinal and vascular degeneration.Drug Discov Today. 2020 Aug; 25(8): 1469-1476. doi:10.1016/j.drudis.2020.03.014 29. Qu J, Xu Y, Zhao S, Xiong L, Jing J, Lui S, HuangJ, Shi H. The biological impact of deuteriumand therapeutic potential of deuteriumdepleted water. Front Pharmacol. 2024 Jul22; 15: 1431204.doi:10.3389/fphar.2024.1431204 30. Boros LG, Kyriakopoulos AM, Brogna C, PiscopoM, McCullough PA, Seneff S. Long-lasting,biochemically modified mRNA, and itsframeshifted recombinant spike proteins inhuman tissues and circulation after COVID19 vaccination. Pharmacol Res Perspect.2024 Jun; 12(3): e1218.doi:10.1002/prp2.1218 31. Cu%u00e9llar Rodr%u00edguez S. Novel drugs recently authorizedby EMA and FDA (Q3, 2024). ANALES RANF[Internet]. Real Academia Nacional de Farmacia;An Real Acad Farm %u00b7 A%u00f1o 2024 %u00b7 volumen 90 %u00b7n%u00famero 03 pp: 369-384.https://doi.org/10.53519/analesranf.2024.90.03.0614. Du Y, Chen Y. The Application of DeuterationStrategy in Drug Design. ChemMedChem.2024 Dec 23: e202400836.doi:10.1002/cmdc.202400836 15. Steverlynck J, Sitdikov R, Rueping M. TheDeuterated %u201cMagic Methyl%u201d Group: A Guideto Site-Selective TrideuteromethylIncorporation and Labeling by UsingCD3 Reagents. Chemistry. 2021Aug 16; 27(46): 11751-11772.doi:10.1002/chem.202101179 16. Chandra Mouli HM, Vinod A, Kumari S, TiwariAK, Kathiravan MK, Ravichandiran V,Peraman R. Deuterated driven new chemicalentities: An optimistic way to improvetherapeutic efficacy. Bioorg Chem. 2023 Jun;135: 106490.Doi:10.1016/j.bioorg.2023.106490 17. Ben Abu N, et al. Sweet taste of heavy water.Commun. Biol. 2021;4:440.doi:10.1038/s42003-021-01964-y 18. Belz TF, et al. Enhancement of a heroin vaccinethrough hapten deuteration. J. Am. Chem.Soc. 2020; 142: 13294%u201313298.doi:10.1021/jacs.0c05219 19. Mourya A, Prajapati N. Precision Deuteration inSearch of Anticancer Agents: Approaches toCancer Drug Discovery. Cancer BiotherRadiopharm. 2024 Feb; 39(1): 1-18.doi:10.1089/cbr.2023.0031 20. Keam SJ, Duggan S. Donafenib: first approval.Drugs. 2021; 81: 1915%u20131920.doi:10.1007/s40265-021-01603-0 21. Llovet JM, Kelley RK, Villanueva A, et al.Hepatocellular carcinoma. Nat Rev DisPrimers 7, 6 (2021).https://doi.org/10.1038/s41572-020-00240-3. A Correction to this paper has beenpublished: https://doi.org/10.1038/s41572-024-00500-6 22. Qian Hj, Wang Y, Zhang Mq, et al. Safety,tolerability, and pharmacokinetics of VV116,an oral nucleoside analog against SARS-CoV2, in Chinese healthy subjects. ActaPharmacol Sin 43, 3130%u20133138 (2022).https://doi.org/10.1038/s41401-022-00895-6 23. Xie Y, Yin W, Zhang Y, et al. Design and developmentof an oral remdesivir derivative VV116 againstSARS-CoV-2. Cell Res 31, 1212%u20131214 (2021).https://doi.org/10.1038/s41422-021-00570-1 Deuterio en Farmacolog%u00edaSantiago Cu%u00e9llar Rodr%u00edguez 469 An. R. Acad. Farm.Vol. 90. n%u00ba4 (2024) %u00b7 pp. 449-470
                                
   81   82   83   84   85   86   87   88   89   90   91